Presentation is loading. Please wait.

Presentation is loading. Please wait.

Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.

Published byΑδελφά Κρεστενίτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet."— Presentation transcript:

1 Metaregression showing the relationship between mortality and antiplatelet strategy.
Metaregression showing the relationship between mortality and antiplatelet strategy. The x-axis shows DAPT duration, including aspirin monotherapy on the far left (blue panel). The y-axis shows the incidence of mortality. Individual studies are represented by circles, with study size weighting giving varying sizes. The red line denotes the gradient (β), with there being of no benefit in terms of DAPT over aspirin for mortality. DAPT, dual antiplatelet therapy. Yousif Ahmad et al. Open Heart 2018;5:e000748 ©2018 by British Cardiovascular Society

Download ppt "Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet."

Similar presentations

Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Mortality risk with dual antiplatelet therapy?

Mortality risk with dual antiplatelet therapy?
Correlation between maximal workload as achieved during a physical exercise test (treadmill or bicycle; horizontal axis) and left superficial femoral artery.

Correlation between maximal workload as achieved during a physical exercise test (treadmill or bicycle; horizontal axis) and left superficial femoral artery.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
John A. Bittl et al. JACC 2016;68:

John A. Bittl et al. JACC 2016;68:
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease  Ehrin.

Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease  Ehrin.
Relationship between the premature ventricular contraction (PVC) prevalence and change in left ventricular diastolic dimension (ΔLVDd) during the 4-year.

Relationship between the premature ventricular contraction (PVC) prevalence and change in left ventricular diastolic dimension (ΔLVDd) during the 4-year.
Baseline Characteristics by Tertiles of Homocysteine

Baseline Characteristics by Tertiles of Homocysteine
ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.
(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.
Comparison of CMR and echocardiography in aortic regurgitation.

Comparison of CMR and echocardiography in aortic regurgitation.
Three-dimensional (3D) measurement of the outer and inner/effective mitral annular area. Three-dimensional (3D) measurement of the outer and inner/effective.

Three-dimensional (3D) measurement of the outer and inner/effective mitral annular area. Three-dimensional (3D) measurement of the outer and inner/effective.

Similar presentations

Ads by Google